Perspective Therapeutics Reports Q1 2026 Financial Results with Increased Assets and Operating Loss

Perspective Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a significant increase in total assets and a notable rise in operating expenses. The company’s total assets reached $410.8 million as of March 31, 2026, up from $267.0 million at the end of 2025, primarily driven by an increase in cash and cash equivalents, which rose to $54.0 million from $30.6 million. However, the company continues to operate at a loss, with a net loss of $26.2 million for the quarter, compared to a net loss of $18.2 million in the same period last year. This resulted in a basic and diluted loss per share of $0.25, consistent with the previous year.

The increase in operating expenses was significant, totaling $28.4 million for the first quarter of 2026, compared to $22.2 million in the prior year, marking a 28% rise. This increase was largely attributed to higher research and development costs, which surged to $21.4 million from $14.3 million, reflecting the company's ongoing investment in clinical trials and personnel. General and administrative expenses decreased slightly to $7.0 million from $7.8 million, primarily due to reduced professional fees. The company’s total operating loss also widened to $28.3 million from $21.8 million year-over-year.

In terms of strategic developments, Perspective Therapeutics successfully completed a registered offering in February 2026, raising approximately $175 million through the sale of common stock and pre-funded warrants. This capital infusion is expected to support the company’s ongoing clinical trials and operational investments. The company is advancing its clinical-stage assets, including VMT-α-NET, VMT01, and PSV359, which are in various phases of clinical trials targeting different cancer types. The company also continues to expand its manufacturing capabilities, having acquired facilities in Houston, Chicago, and Los Angeles, which are expected to enhance production capacity for its radiopharmaceutical candidates.

Operationally, Perspective Therapeutics is focused on increasing its clinical trial enrollment and product adoption rates. As of April 30, 2026, the company had treated a total of 64 patients across its clinical trials, with ongoing studies aimed at optimizing treatment regimens. The company’s cash, cash equivalents, and short-term investments totaled $270.9 million as of March 31, 2026, which management believes will be sufficient to fund operations into late 2027. However, the company anticipates that it will need to raise additional capital to support its growth and development initiatives, as it has historically operated at a loss and does not yet generate revenue from commercial products.